Humacyte reported second quarter 2026 results showing commercial sales of Symvess increased to $0.4 million from $0.1 million in the prior year period. The company announced breakthrough Phase 3 data for its ATEV dialysis access product, where it outperformed AV fistula in female patients, and plans to file a supplemental Biologics License Application with the FDA later this year. Additionally, the FDA accepted an IND application for CTEV, initiating a Phase 2a study for coronary artery bypass grafting expected in Q3 2026. Humacyte raised $57.5 million via public offering in June and implemented workforce reductions estimated to save $14.3 million annually. The company operates as a commercial-stage biotechnology platform developing bioengineered human tissues.
